Liquidia Technologies
Liquidia Corporation focuses on developing and commercializing products for pulmonary hypertension using its proprietary PRINT® technology.
Company Overview
Liquidia Corporation, founded in June 2004, specializes in developing and commercializing products for pulmonary hypertension and other applications using its proprietary PRINT® technology. The company operates through two wholly owned subsidiaries: Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia’s headquarters are located in Morrisville, North Carolina. Liquidia is incorporated in Delaware and its common stock is listed on the Nasdaq Capital Market under the symbol 'LQDA'.
PRINT® Technology
Liquidia's proprietary PRINT® technology allows for the precise engineering and manufacturing of highly uniform drug particles. This technology enables the development of drug particles with controlled size, shape, and chemical composition, enhancing pharmacological benefits. PRINT® technology is modular, scalable, and cost-effective. It allows for improved drug particle deposition in the lung following oral inhalation, making it a significant innovation in drug delivery systems.
YUTREPIA™ (Treprostinil) Inhalation Powder
Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). This product is designed to enhance drug delivery and deep-lung penetration with a precise size and highly uniform shape of particles. YUTREPIA™ leverages Liquidia’s PRINT® technology to improve the pharmacological efficacy of the treatment.
Subsidiaries: Liquidia Technologies and Liquidia PAH
Liquidia operates through two subsidiaries: Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies focuses on developing innovative products using PRINT® technology, including YUTREPIA™ for PAH. Liquidia PAH is dedicated to the commercialization of rare disease pharmaceutical products, such as the generic Treprostinil Injection, which is the first-to-file, fully substitutable generic treprostinil for parenteral administration.
Investigational Products: L606
Liquidia’s L606 is an investigational, sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer. L606 uses Pharmosa Biopharm’s proprietary liposomal formulation to encapsulate treprostinil, enhancing drug exposure over an extended period. L606 aims to improve the management and treatment outcomes for patients with pulmonary arterial hypertension.